Summary
samenvatting immunologie I
- Course
- Institution
volledige samenvatting van het eerste deel van immunologie I gegeven in het 2de jaar biomedische laboratoriumtechnologie
[Show more]
Seller
Follow
heleen_t
Content preview
Immunologie I DEEL 11
,INHOUDSOPGAVE
1 INLEIDING ...................................................................................................................................................... 5
1.1 DEF ................................................................................................................................................................. 5
1.2 HISTORIEK ........................................................................................................................................................ 5
1.3 VACCINATIE ...................................................................................................................................................... 5
2 PATHOGENESE............................................................................................................................................... 6
2.1 ALGEMENE BEGRIPPEN ........................................................................................................................................ 6
2.2 INFECTIEPROCESSEN ........................................................................................................................................... 6
3 VERDEDIGINGSMECHANISMEN ..................................................................................................................... 7
3.1 NATUURLIJKE BARRIÈRES ..................................................................................................................................... 7
3.2 AANGEBOREN EN VERWORVEN IMMUUNSYSTEEM .................................................................................................... 7
3.2.1 Aangeboren immuunstysteem .............................................................................................................. 8
3.2.1.1 cellen van het aangeboren immuunsysteem ................................................................................................... 8
3.2.1.2 Antimicrobiële eiwitten ................................................................................................................................. 10
3.2.1.3 Herkenning patronen op micro-organismen.................................................................................................. 10
3.2.2 Ontsteking ........................................................................................................................................... 11
3.2.2.1 Acute ontstekingsreactie ............................................................................................................................... 11
3.2.2.2 Chemische mediatoren .................................................................................................................................. 11
3.2.2.3 Acute fase reactie .......................................................................................................................................... 12
3.2.2.4 Chronische ontsteking ................................................................................................................................... 13
3.2.2.5 Ontstekingsreactie is betrokken bij vele vormen van afweer ........................................................................ 13
3.2.3 Verworven immuunsysteem ................................................................................................................ 13
3.2.3.1 Begrippen ....................................................................................................................................................... 13
3.2.3.2 Informatiebronnen ........................................................................................................................................ 14
3.3 SAMENVATTING VERWORVEN IMMUUNSYSTEEM: ................................................................................................... 17
4 CELLEN VAN HET VERWORVEN IMMUUNSYSTEEM...................................................................................... 18
4.1 SOORTEN ....................................................................................................................................................... 18
4.1.1 Lymfocyten .......................................................................................................................................... 18
4.1.2 Fagocyten ............................................................................................................................................ 18
4.1.2 Andere ................................................................................................................................................. 18
4.2 LYMFOCYTEN IN DETAIL ..................................................................................................................................... 19
4.3 ONTWIKKELING VAN DIVERSITIET ......................................................................................................................... 21
4.4 ONTSTAAN VAN LYMFOCYTEN............................................................................................................................. 24
4.5 DIFFERENTIATIE VAN DE B-LYMFOCYTEN IN HET BEENMERG ...................................................................................... 26
4.6 DIFFERENTIATIE VAN T-LYMFOCYTEN IN DE THYMUS................................................................................................ 28
4.7 SAMENVATTING CELLEN VAN HET VERWORVEN IMMUUNSYSTEEM.............................................................................. 30
5 MAJOR HISTOCOMPATIBILITY COMPLEX ..................................................................................................... 32
5.1 MHC-KLASSA-I-MOLECULEN .............................................................................................................................. 32
5.2 MHC-KLASSE-II-MOLECULEN ............................................................................................................................. 33
5.3 POLYMORFISME – CO-DOMINANTIE .................................................................................................................... 34
5.4 FUNCTIES MHC-MOLECULEN ............................................................................................................................. 34
5.5 SAMENVATTING MAJOR HISTOCOMPATIBILITY COMPLEX .......................................................................................... 36
6. CELLULAIRE IMMUNITEIT ........................................................................................................................... 37
6.1 T-CELRECEPTOREN ........................................................................................................................................... 37
6.1.1 Cytotoxische T-cellen (Tc of CTL) ......................................................................................................... 37
6.1.2 T-helper cellen (Th cellen) .................................................................................................................... 37
6.2 CELLULAIRE IMMUUNRESPONS............................................................................................................................ 38
6.2.1 CD4+ Th-lymfocyten oefenen functie uit d.m.v. cytokinen .................................................................. 41
6.2.2 CD8+ cytotoxische T-lymfocyten .......................................................................................................... 43
6.2.3 CTL belangrijk voor afweer tegen tumorcellen .................................................................................... 44
6.2.4 Cellen verantwoordelijk voor cellulair immunologisch geheugen: centrale en effectorgeheugencellen
...................................................................................................................................................................... 45
2
, 6.2.5 Verschillende mechanismen regelen duur en omvang cellulaire respons ........................................... 45
6.3 SAMENVATTING CELLULAIRE IMMUNITEIT.............................................................................................................. 45
7. HUMORALE IMMUNITEIT ........................................................................................................................... 47
7.1 ANTILICHAMEN (AL)......................................................................................................................................... 47
7.2 INDELING........................................................................................................................................................ 47
7.3 HUMORALE IMMUUNRESPONS ........................................................................................................................... 48
7.3.1 Affiniteit en aviditeit --> bepalen sterkte interactie tussen AG en AL .................................................. 48
7.3.2 Volledige activatie en differentiatie rijpe B-lymfocyten vereist twee signalen .................................... 49
7.2.3 Activatie van B-lymfocyten door koolhydraten ................................................................................... 51
7.2.4 Transcriptiefactoren bepalen of geactiveerde B-lymfocyten uitrijpen tot plasmacellen of
differentiëren tot geheugenlymfocyten ........................................................................................................ 51
7.2.5 Affiniteitsrijping tijdens humorale immuunrespons ............................................................................ 51
7.2.5.1 Dimere en polymere AL ................................................................................................................................. 52
7.2.5.2 Isotype switching ........................................................................................................................................... 52
7.2.6 Activatie B-lymfocyten door AG-specifieke CD4+ effector-Th-lymfocyten in secundair lymfoïde
organen ........................................................................................................................................................ 53
7.4 VERDELING EN FUNCTIE VAN IMMUNOGLOBULINEN IN HET LICHAAM .......................................................................... 53
7.4.1 IgM ...................................................................................................................................................... 54
7.4.2 IgG ....................................................................................................................................................... 55
7.4.3 IgA ....................................................................................................................................................... 55
7.4.4 IgD ....................................................................................................................................................... 55
7.4.5 IgE ........................................................................................................................................................ 55
7.5 PRIMAIRE EN SECUNDAIRE HUMORALE IMMUUNRESPONS ........................................................................................ 56
7.6 REGULATIE VAN DE HUMORALE IMMUUNRESPONS .................................................................................................. 57
7.7 FUNCTIES VAN DE B-LYMFOCYT ........................................................................................................................... 58
7.8 SAMENVATTING HUMORALE IMMUNITEIT ............................................................................................................. 58
8 HET COMPLEMENTSYSTEEM ........................................................................................................................ 60
8.2 KLASSIEKE ACTIVERINGSROUTE ............................................................................................................................ 60
8.3 MANNOSEBINDEND-LECTINEROUTE ..................................................................................................................... 61
8.4 ALTERNATIEVE ROUTE ....................................................................................................................................... 61
8.5 ACTIVATIE VAN COMPLEMENTFACTOR C3 ............................................................................................................. 62
8.6 COMPLEMENT STIMULEERT ONTSTEKINGSREACTIE ................................................................................................... 62
8.7 SAMENVATTING COMPLEMENTSYSTEEM................................................................................................................ 63
9 CYTOKINEN .................................................................................................................................................. 64
9.1 TUMORNECROSEFACTOR-Α (TNF-Α ) EN INTERLEUKINE-1 (IL-1) ............................................................................... 64
9.3 INTERLEUKINE-2 (IL-2) ..................................................................................................................................... 65
9.4 INTERLEUKINE-3 (IL-3) ..................................................................................................................................... 65
9.5 INTERLEUKINE-4 (IL-4) EN INTERLEUKINE-5 (IL-5) ................................................................................................. 65
9.6 INTERLEUKINE-6 (IL-6) ..................................................................................................................................... 65
9.7 INTERLEUKINE-12 (IL-12) ................................................................................................................................. 65
9.8 INTERLEUKINE-15 (IL-15) ................................................................................................................................. 65
9.10 CHEMOKINEN CXCL8 (IL-8) EN CCL2 (MCP-1) ................................................................................................. 65
9.11 INTERFERON (IFN) ......................................................................................................................................... 66
10 MONOKLONALE ANTILICHAMEN ............................................................................................................... 67
10.1 PRODUCTIE MONOKLONALE ANTILICHAMEN TEGEN BEPAALD AG ............................................................................. 67
10.2 SOORTEN MONOKLONALE AL ........................................................................................................................... 68
11 INFECTIES EN INFECTIEZIEKTEN.................................................................................................................. 69
11.1 AFWEER TEGEN EXTRACELLULAIRE BACTERIËN ...................................................................................................... 69
11.2 AFWEER TEGEN INTRACELLULAIRE BACTERIËN ...................................................................................................... 70
11.3 AFWEER TEGEN INTRACELLULAIRE VIRUSSEN ........................................................................................................ 70
11.4 AFWEER TEGEN SCHIMMELS ............................................................................................................................. 71
11.5 PARASIETEN .................................................................................................................................................. 72
3
, 11.6 MICRO-ORGANISMEN EN PARASIETEN ONTSNAPPEN AAN HET I.S. (= EVASIE) ............................................................. 73
11.6.1 Evasie door AG variatie (verandering van AG opmaak) .................................................................... 73
11.6.2 M.o. produceren eiwitten die antilichamen kunnen afbreken of inactiveren .................................... 75
11.6.3 Bacteriën en virussen produceren eiwitten die complement-activatie remmen ............................... 75
11.6.4 Interferentie met antigeenpresentatie maakt virussen onzichtbaar voor herkenning door T-
lymfocyten .................................................................................................................................................... 75
11.6.5 Virale homologen van cytokinen en cytokinereceptoren en andere eiwitten onderdrukken de
antivirale immuniteit .................................................................................................................................... 76
4
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller heleen_t. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $9.29. You're not tied to anything after your purchase.
Can Stuvia be trusted?
4.6 stars on Google & Trustpilot (+1000 reviews)
80364 documents were sold in the last 30 days
Founded in 2010, the go-to place to buy study notes for 14 years now